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Abstract 
Background: The use of opioids is increasing in children; therefore, opioid toxicity could be a public health problem 
in this vulnerable population. However, we are not aware of a published algorithm to identify cases of opioid toxic-
ity in children using administrative databases. We sought to develop an algorithm to identify them. After review of 
literature and de-identified computer profiles, a broad set of ICD-9 CM codes consistent with serious opioid toxicity 
was selected. Based on these codes, we identified 195 potential cases of opioid toxicity in children enrolled in Tennes-
see Medicaid. Medical records were independently reviewed by two physicians; episodes considered equivocal were 
reviewed by an adjudication committee. Cases were adjudicated as Group 1 (definite/probable), Group 2 (possible), or 
Group 3 (excluded).
Results: Of the 195 potential cases, 168 (86.2%) had complete records for review and 85 were confirmed cases. The 
overall positive predictive value (PPV) for all codes was 50.6%. The PPV for codes indicating: unintentional opioid 
overdose (25/31) was 80.7%; intentional opioid overdose (15/30) was 50.0%, adverse events (33/58) was 56.9%, the 
presence of signs or symptoms compatible with opioid toxicity (12/47) was 25.5%, and no cases were confirmed in 
records from the two deaths. Of the confirmed cases, 65.8% were related to therapeutic opioid use.
Conclusion: For studies utilizing administrative claims to quantify incidence of opioid toxicity in children, our find-
ings suggest that use of a broad set of screening codes coupled with medical record review is important to increase 
the completeness of case ascertainment.
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Background
There is a well-recognized epidemic of hospitalizations 
and deaths related to the increasing use of opioid anal-
gesics in adults [1–3]. From 1999 to 2008 in the United 
States, rates of opioid sales, toxicity, and death related to 
opioid use tripled, and recent data indicate that opioid 
toxicity accounts for 73.8% of all deaths attributed to a 
prescription drug [4].
Although there are fewer studies in children, this 
vulnerable population also appears to be at high risk 
for opioid toxicity. A study of 960 randomly selected 
medical records from 12 children’s hospitals identified 
107 adverse drug events with more than half attribut-
able to opioid analgesics [5]. Deaths have been reported 
in young children related to therapeutic use of codeine 
[6] and hydrocodone [7] in doses within or moderately 
exceeding recommended pediatric limits.
Despite their potential for serious adverse events, opi-
oids are increasingly prescribed for adolescents. Opioid 
prescriptions for patients between 15 and 19 years of age 
doubled from 1994 to 2007, with estimates that opioids 
are prescribed in nearly 6% of ambulatory and emergency 
department visits made by adolescents in the US [8].
Given the large number of pediatric patients receiving 
prescribed opioids, there is an urgent need for fundamen-
tal epidemiologic studies to inform the risk–benefit deci-
sions of prescribers and families. An essential component 
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of these epidemiologic studies is the identification of seri-
ous adverse reactions related to opioids. Epidemiologic 
studies in adults have developed procedures to identify 
hospitalizations and deaths related to opioid use [3, 9]. 
However, we are unaware of similar studies in children.
Studies specifically aiming to evaluate children are impor-
tant because there are significant differences between children 
and adults. For example, during growth and development, 
changes in drug metabolizing enzyme activity result in age-
related differences in drug disposition [10]. Moreover, focus 
on only deaths and hospitalizations is likely to underestimate 
the occurrence of serious adverse events in pediatric practice, 
given the low frequency of these events in children. Thus, the 
primary purpose of the present study was to develop and test 
procedural tools for identification of opioid toxicity in chil-
dren for a broad spectrum of adverse events, including visits to 
emergency departments, hospital admissions, and deaths. The 
secondary purpose was to assess the positive predictive value 
(PPV) of specific groups of diagnostic codes.
We designed our procedures for large administrative 
databases, given their recognized utility for pharmacoep-
idemiology [11]. This process included the identification 
of medical encounters in children likely to indicate seri-
ous opioid toxicity, procedures for adjudication of cases 
of possible opioid toxicity, and acquiring preliminary data 
on the PPV of the screening procedures as well as the cir-




The study was conducted in children 2–17  years of age 
enrolled in the Tennessee Medicaid program between 
1999 and 2011. This setting was chosen because Tennes-
see Medicaid included large numbers of children (49.7% 
of all Tennessee Medicaid enrollees) and the Medicaid 
files permitted efficient identification of children who 
filled a prescription for an opioid, potential adverse 
opioid effects, and pertinent demographic and clinical 
covariates [11]. Study files included enrollment, phar-
macy (filled prescription), outpatient and inpatient visits, 
as well as linked state hospital discharge (with emergency 
department visits) and death certificate files [11].
Cohort and follow‑up
We sought to reduce the confounding by symptoms 
related to terminal illness and serious medical disorders. 
Therefore, we excluded children with prior medical care 
encounters indicating serious illnesses in the previous 
12 months (including cancer, sickle cell anemia, congeni-
tal anomalies, etc.), history of organ transplant, institu-
tional residence, and/or history of drug abuse (Table  5 
in “Appendix”). For each child in the cohort and for each 
opioid prescription filled by that child, study follow-up 
included the period between the filling of the prescrip-
tion and 14  days following the end of the prescribed 
days of supply. Although opioid toxicity most commonly 
occurs during current use of the drug, adverse events 
may delayed, or, given that opioids are often prescribed 
to be taken “as needed”, the period of actual use may 
extend beyond the dispensed days of supply.
Development study sample
Our ultimate goal is to study the epidemiology of serious 
opioid toxicity in a large cohort of children prescribed 
opioids. Our strategy for identifying serious opioid toxic-
ity was to first identify potential cases from medical care 
encounters and then to confirm these by adjudication of 
medical records. The purpose of the current development 
study was to test and refine the procedures for identify-
ing opioid-related adverse events. The development study 
was restricted to encounters at five major centers with a 
high volume of Tennessee Medicaid pediatric patients for 
which we had access to medical records.
Medical encounters indicating opioid toxicity
Clinical spectrum of opioid toxicity
Opioids have a wide range of adverse effects [12]. The 
most serious is overdose, nearly always accompanied 
by respiratory or central nervous system (CNS) depres-
sion [13–15]. Other adverse effects include milder CNS 
effects, constipation, nausea, vomiting, dermatologic 
reactions, urinary retention, myoclonus, seizures (with 
meperidine) and metabolic disorders [12, 14, 16].
Encounters indicating potential cases of opioid toxicity
Serious opioid toxicity was defined as Group 1: definite/
probable, or Group 2: possible based on medical record 
review. Encounters of interest were restricted to emer-
gency department visits, hospital admissions, and deaths. 
Potential cases were identified from ICD-9-CM diagnos-
tic codes, either primary or secondary, recorded for the 
encounter.
There were four groups of codes. First, were the exter-
nal cause of injury codes that indicate medication poison-
ing/overdose (Table  6 in “Appendix”). Because all cohort 
follow-up consisted of either current or very recent use of 
an opioid, we hypothesized there was a considerable prior 
probability of opioid involvement in an adverse drug reac-
tion. Thus, in this development study, we included codes 
that indicated an opioid or unspecified analgesic (codes 
in Group A of tables) as well as those that indicated an 
unspecified medication (codes in Group C of the tables), 
unless the encounter also indicated a specific drug that 
was not an opioid (codes in Group B). We did not consider 
encounters with other specified medications, because, 
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given that the reaction had been attributed to another 
drug (e.g., hypoglycemia related to insulin), we thought it 
would be unlikely to be adjudicated as due to an opioid. 
Second, were the external cause of injury codes indicating 
an adverse effect in therapeutically appropriate use (Table 7 
in “Appendix”). Third, were diagnosis codes indicating 
symptoms of the most serious opioid toxicity: respiratory 
depression and adverse CNS effects (Table  8 in “Appen-
dix”), even in the absence of an external cause of injury 
code. Finally, records for all deaths during follow-up were 
reviewed, regardless of the cause of death diagnosis codes.
There were several other groups of codes initially con-
sidered but ultimately not included in those for identify-
ing potential cases. These included diagnoses indicating 
symptoms possibly due to less serious toxicity (such as rash, 
nausea, or constipation) in the absence of a code indicat-
ing an adverse drug effect. These were excluded because 
of the large number of such encounters and the difficulty 
of attributing them to an opioid even with medical record 
review. We also excluded some less specific codes for res-
piratory and CNS symptoms (e.g., dizziness), based on their 
relative commonness, difficulty of attribution to an opioid, 
analysis of computer profiles, and preliminary analysis of 
the development study data. We initially considered symp-
toms related to metabolic disorders, but preliminary analy-
sis suggested these were infrequent and had poor PPV. We 
also considered administration of naloxone as an indicator 
of overdose, but a preliminary review indicated that nalox-
one was most frequently used to reverse the effects of opi-
oid administration following a surgical procedure. However, 
naloxone use did not trigger exclusion from the cohort.
Adjudication procedures
After de-identification, all medical records were indepen-
dently reviewed and adjudicated by two study physicians 
(STC and CPC) using the study instrument (Figure 1 in 
“Appendix”). Episodes for which there was disagree-
ment among adjudicators were subsequently adjudicated 
by all the investigators. Following standard procedures, 
we reviewed complete medical records for evidence of 
symptoms and signs clearly attributed to opioid toxicity 
with no other process implicated. Other clinical infor-
mation included temporal sequence of events, medical 
interventions, escalation of care and evidence of symp-
toms or signs attributable to other causes. Consensus was 
reached after discussion of all available evidence.
Adjudicated episodes were classified into one of the fol-
lowing mutually exclusive categories:
Group 1: Definite/Probable opioid toxicity There were 
two scenarios:
1. The presence of both of the following criteria: (1) 
signs and symptoms compatible with opioid toxicity 
and attributed by the treating physician as related to 
an opioid poisoning, overdose or adverse event; and 
(2) no other drug or disease process implicated in the 
presence of these signs or symptoms.
2. Direct intervention or escalation of care because of 
potential opioid toxicity (for example: admission to 
the Intensive Care Unit after inadvertent overdose of 
hydrocodone).
Group 2: Possible opioid toxicity These episodes met 
both of the following criteria: (1) signs or symptoms com-
patible with opioid toxicity that were not clearly attrib-
uted directly to opioid toxicity but not attributed to other 
causes; and (2) the temporal sequence suggested that opi-
oid use was a possible cause of signs or symptoms.
Group 3: excluded, opioid toxicity unlikely There were 
three scenarios in which opioid toxicity was excluded:
1. Presence of signs or symptoms compatible with opi-
oid toxicity but attributed to other causes (for exam-
ple: vomiting attributed to gastrointestinal infection 
by treating physician).
2. Presence of signs and/or symptoms compatible with, 
but not clearly attributed to opioid toxicity (but not 
attributed to other causes either); and lack of a tem-
poral sequence suggesting that opioids were a possi-
ble cause of signs or symptoms.
3. Neither signs nor symptoms compatible with opioid 
toxicity nor escalation of care because of potential 
opioid toxicity.
Our definition did not consider findings from urine and 
serum drug screens for opioids. These were not consist-
ently performed and have been shown to have limited 
utility in the diagnosis of acute opioid toxicity [12].
Severity of the outcome
Cases that met the criteria for probable or possible opioid 
toxicity were classified according to severity of the event:
a. Death: attributed to opioid.
b. High: the adverse effect resulted in hospitalization or 
escalation of care or management.
c. Intermediate: the opioid-related symptoms were the 
primary reason for an emergency room visit.
d. Low: the opioid-related symptoms were an incidental 
or minor part of the encounter.
Opioid exposure
For each probable or possible case, we also recorded 
both the circumstances of the opioid exposure as well 
as the source of the opioid. The circumstances of expo-
sure included: (1) self-harm—any indication of attempted 
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suicide or intentional overdose, (2) recreational ingestion, 
(3) unintentional overdose—e.g., parent inadvertently 
administered an extra dose, (4) therapeutic use—the medi-
cation was taken as prescribed, (5) opioid withdrawal, (6) 
unspecified—no indication of circumstances or intent doc-
umented. The source of the opioid related to the adverse 
event was: (1) the patient’s prescription, (2) another per-
son’s prescription, (3) an illegal source, or (4) not specified.
Statistical analyses
Statistical analyses were conducted in two steps. First, 
tables were constructed specifying whether clinical crite-
ria for opioid toxicity (definitive, probable and possible) 
were met according to review of medical records and 
PPVs were calculated. Secondary analyses included cal-
culation of PPV according to time elapsed since the end 
of the days of supply (through 7 days and 8–14 days).
Cases adjudicated as Group 1 (definite/probable) or 
Group 2 (possible) opioid toxicities were further classi-
fied by severity and by exposure, as detailed above. Sec-
ond, based on final adjudication, positive predictive values 
were calculated. Reliability was expressed as kappa statis-
tics, excluding 12 initial cases used to refine the adjudi-
cation procedures. Analyses were conducted with the use 
of STATA 12 (StataCorp. 2011. Stata Statistical Software: 
Release 12, College Station, TX: StataCorp LP).
The study was approved by the Institutional Review 




Based on the screening codes (listed in the “Appendix”), 
195 potential cases of opioid toxicity in children from five 
hospitals in Tennessee were identified. These children 
were 11.3 ± 5.0 years old on average and predominantly 
Caucasian (59%) and female (57%).
Positive predictive value
From the 195 potential cases, records for four cases (2%) 
did not have enough information to adjudicate and 23 (12%) 
were not found. Of the 168 remaining potential cases, 85 
were adjudicated as Group 1 (definite/probable) or Group 2 
(possible) opioid toxicity event (PPV = 50.6%) (Table 1).
We calculated PPVs for specific diagnostic codes. Of 
31 potential cases identified as unintentional poisoning/
overdose, 25 were confirmed (PPV  =  80.7%). Thirty-
three of the 58 cases identified based on codes for adverse 
effect of drugs in therapeutic use were confirmed, with a 
PPV = 56.9%. Lower PPVs were found for patients with 
codes indicating intentional overdose (PPV  =  50.0%), 
or symptoms compatible with opioid toxicity (25.5%). 
Although the numbers were small, cases identified on 
the basis of CNS symptoms had a PPV = 28.1%. The PPV 
for cases identified based on respiratory symptoms was 
lower (20.0%) (Table 2). There were two deaths, but after 
review of records the causes of death in both cases were 
not compatible with opioid toxicity.
We calculated the PPVs according to the time elapsed 
since the end of the days of supply (Table 3). There were 121 
cases identified between the filling of the prescription and 
7 days following the end of the days of supply, of which 69 
were confirmed, with a PPV = 57.0%. Of the potential 47 
potential cases identified 8–14 days after the end of the days 
of supply, 16 were confirmed (PPV = 34.0%).
Severity of outcome, intent, and source of the opioid
With regard to the severity of the outcomes, 27 (31.8%) 
cases were classified as high, 52 (61.2%) as intermediate, 
and six (7.1%) as low severity. Based on intent of opioid use, 
56 (65.8%) cases were related to therapeutic use, 10 (11.8%) 
to self-harm, nine (10.6%) to unintentional overdose, and 
Table 1 Positive predictive value for  codes identifying 
potential opioid toxicity in children
PPV positive predictive value.
a Confirmed = Group 1 (definitive/probable) or Group 2 (possible).
Total Confirmeda
n PPV (%)
Overall 168 85 50.6
Stratified analyses by type of diagnosis
 Opioid overdose, intentional 30 15 50.0
 Opioid overdose, unintentional 31 25 80.7
 Potential opioid adverse effect 58 33 56.9
 Symptoms indicative of opioid overdose 
(CNS, respiratory)
47 12 25.5
 Death, any cause 2 0 0
Table 2 Utility of symptom screening codes
n n, confirmed PPV (%)
All symptoms 47 12 25.5
 CNS 32 9 28.1
 Respiratory 15 3 20.0
Table 3 Positive predictive values for  screening codes 
according to time since end of days of supply
n n, confirmed PPV (%)
Entire sample 168 85 50.6
Date of prescription fill through 7 days 
following end of days of supply
121 69 57.0
Days 8–14 following end of days of 
supply
47 16 34.0
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four (4.7%) to recreational use of opioids. There was one 
case with records indicating opioid withdrawal and in six 
cases (7.1%) it was not possible to determine the intent. We 
also assessed the source of opioid. The majority of the cases 
(n =  76, 89.4%) had records supporting the use of a pre-
scribed opioid, while the use of another person’s prescrip-
tion was noted in only four cases. There were no cases with 
indication of an illegal source and in six cases (7.1%) it was 
not possible to specify the source (Table 4).
Inter‑rater agreement
All cases were initially reviewed by two clinicians. From 
the 156 cases available for estimation of inter-rater reli-
ability, 13 cases were brought to the adjudication com-
mittee for further discussion. There was agreement 
in 91.7% (the expected agreement was 50.6%) and the 
kappa statistics was 0.83 (p  <  0.001). In eight of these 
13 cases, one reviewer initially adjudicated the case as 
Group 2 (possible) and the other as Group 3 (exclusion).
Discussion
To the best of our knowledge, this is the first study 
describing the development and validation of a procedural 
tool, based on identification of potential cases with ICD 
codes and adjudication of individual cases with review 
of medical records, to identify opioid toxicity in children 
for use in pharmacoepidemiologic studies in automated 
databases. Our analyses showed that the study codes for 
identifying adverse opioid effects had a low PPV, which 
suggests that review of medical records is important.
Many symptoms of opioid toxicity have a broad differen-
tial diagnosis and may be related to other concurrent fac-
tors, including other medications [17]. Furthermore, it is 
well recognized that medications affect children and adult 
differently. Although others have developed procedures 
to identify fatal cases of opioid overdose from diagnosis 
codes [3], these results are not necessarily applicable to 
non-fatal outcomes. Furthermore, we cannot assume that 
data from adults are necessarily applicable to children.
Thus, we identified a set of screening codes for opioid 
toxicity specifically for a pediatric population. To adju-
dicate potential cases, we followed a detailed procedure 
that began with confirming the presence of symptoms or 
signs compatible with opioid toxicity. We excluded cases in 
which the treating physician attributed the symptoms and 
signs to other causes. The temporal sequence of events and 
intervention/escalation of care were also considered. The 
initial complete review of each medical record and its adju-
dication were done by two experienced physicians, blinded 
to the other’s adjudication. Although the interrater reliabil-
ity kappa of 0.84 indicates substantial agreement [18]; there 
were 7.7% cases in which the reviewers disagreed. Thus, 
our adjudication process should improve accuracy relative 
to review and adjudication by a single investigator.
Although the overall PPV was low, PPVs differed greatly 
according to the type of diagnosis. Cases that were identi-
fied based on codes indicating opioid or analgesic unin-
tentional overdose/poisoning had the highest PPV; but 
they only accounted for 25 of the 85 (29.4%) confirmed 
cases. This suggests that studies to quantify the inci-
dence of opioid adverse effects should not be limited to 
these codes. In contrast, cases identified based on diag-
nosis codes consistent with symptoms of opioid toxicity, 
but with no mention of a drug, had a PPV of only 25.5%. 
However, such cases accounted for 12 (14.1%) of the con-
firmed cases. Therefore, failure to use symptom-related 
codes will lead to underestimation of the incidence of opi-
oid toxicity.
Several limitations should be considered. First, deter-
mination of causality was based primarily on the judg-
ment of the treating physician, as documented in the 
medical records. This limitation, inherent to retrospec-
tive studies, may be particularly important for less seri-
ous opioid adverse effects with multiple causes, such as 
dermatologic or gastrointestinal reactions. Second, the 
algorithm was developed to identify cases of opioid toxic-
ity related to hospitalization or an emergency department 
visit; thus, less serious events were not captured. Third, 
because the present study is restricted to children with 
a filled opioid prescription, our procedures are designed 
for study of therapeutic use of opioids. Fourth, 11.8% of 
records, primarily from early years, were unavailable 
for review, most commonly because the records were 
already destroyed. Fifth, we do not include data on treat-
ment duration. Finally, the study was conducted in chil-
dren enrolled in Tennessee Medicaid, and because our 
primary area of concern was relatively healthy children 
receiving opioids therapeutically we exclude children 




 High 27 31.8
 Intermediate 52 61.2
 Low 6 7.1
Intent
 Therapeutic use 56 65.8
 Self-harm 10 11.8
 Unintentional overdose 9 10.6
 Other 11 13.0
Source of opioid
 Patient’s prescription 76 89.4
 Other person’s prescription 4 4.7
 Other 6 7.1
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with serious conditions, which may limit generalizability 
to other databases and clinical settings.
Conclusion
In summary, the overall positive predictive value of diag-
nosis codes indicating opioid toxicity was low. Our find-
ings suggest that for incidence studies, a two-step process 
would allow inclusion of a broader range of screening 
diagnostic codes and thus would capture a larger fraction 
of cases of opioid toxicity in the study population.
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Figure 1 Child opioid study adjudication/summary form.
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Table 5 Serious illnesses
Disease Definition
Cancer Diagnosis of cancer (except for non-melanoma skin cancers)
Selected antineoplastic agents
Hematologic diseases Sickle cell diagnosis, aplastic anemia
Neuromuscular diseases Cerebral palsy, muscular dystrophy, multiple sclerosis, ALS, quadriplegia, paraplegia, hemiplegia, 
spinal cord injury, stroke
Chromosomal anomalies Down’s syndrome, trisomy 13, trisomy 18, autosomal deletion syndrome and others
Other congenital anomalies-non cardiovascular Cystic fibrosis, anencephalus, spina bifida, hydrocephalus, microcephalus, encephalocele
Congenital anomalies-cardiovascular Common truncus, transposition great vessels, tetralogy of Fallot, common ventricle, endocardial 
cushion defect, pulmonary atresia, tricuspid atresia, hypoplastic left heart, coarctation of aorta, other 
anomalies of aorta, total anomalous pulmonary venous connection
Gastrointestinal diseases Ulcerative colitis, Crohn’s disease
Liver disease: acute and subacute necrosis of the liver, chronic liver disease and cirrhosis, hepatic 
encephalopathy, portal hypertension, hepatorenal syndrome, other sequelae of chronic liver 
disease, other disorders
Hospitalization for any other liver disease: abscess of the liver, portal pyemia, hepatopulmonary syn-
drome, other specified disorders of the liver
Acute or chronic pancreatitis
Mental retardation Moderate to profound intellectual disability
HIV and other serious infections Diagnosis of HIV
Use of antiretroviral agents appropriate for HIV or pentamidine
Hepatitis B and/or C
Treatment for viral hepatitis
Tuberculosis
Treatment for tuberculosis
Other immunologic conditions Immune deficiencies (deficiency of humoral immunity, deficiency of cell-mediated immunity, com-
bined immunity deficiency, unspecified immunity deficiency)
Renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital
Cardio-respiratory diseases Any diagnosis of primary pulmonary hypertension
Inpatient diagnosis of chronic respiratory failure, cardio-respiratory failure, or pulmonary heart disease
Tracheostomy (excluding temporary)
Organ transplant Includes kidney, heart, lung, liver, bone marrow, and pancreas
Medications: azathioprine, cyclosporine, tacrolimus (except derm preparation), mycophenolate 
mofetil, mycophenolate sodium, sirolimus, daclizumab, antithymocyte immune, bevacizumab, 
basiliximab, muromonab
Other serious illness Hospice care
Diagnosis of coma, vegetative state, debility, cachexia
Total parenteral nutrition/gastrostomy
Gangrene
Intravenous medications outside of the hospital
Severe metabolic disorders: disturbances of the amino-acid transport, disturbances of carbohydrate, 
mucopolysaccharidosis, other specified disorders of the metabolism
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Table 6 ICD9-CM diagnosis codes indicating potential medication overdose
Codes with an * denote possible intentional injuries. Unlike Dunn and colleagues [3], we do not include codes for intentional injuries where these specify a means 
other than drug (e.g. firearm). We also do not include the injury codes for unspecified means; preliminary review established these were nearly all E988.9, and had 
little probability of relation with an endpoint.
Code Diagnosis
A. Opioid or unspecified analgesic
 1. 965.0 Poisoning by analgesics, antipyretics, and antirheumatics, opiates and related narcotics
 2. 965.8 Other specified analgesics and antipyretics, pentazocine
 3. 965.9 Unspecified analgesic and antipyretic
 4. E850.0 Accidental poisoning by analgesics, antipyretics, and antirheumatics, heroin
 5. E850.1 Accidental poisoning by analgesics, antipyretics, and antirheumatics, methadone
 6. E850.2 Accidental poisoning by analgesics, antipyretics, and antirheumatics, other opiates and related narcotics
 7. E850.8 Accidental poisoning by analgesics, antipyretics, and antirheumatics, pentazocine
 8. E850.9 Accidental poisoning by analgesics, antipyretics, and antirheumatics, unspecified analgesic or antipyretic
 9. E950.0* Self-inflicted injury, analgesics, antipyretics, and antirheumatics
 10. E980.0* Injury undetermined whether accidentally or purposely inflicted, analgesics, antipyretics, and antirheumatics





C. Unspecified medication or substance
 15. 292.1 Drug-induced psychotic disorders
 16. 292.2 Pathological drug intoxication
 17. 292.8 Other specified drug-induced mental disorders
 18. 292.9 Unspecified drug-induced mental disorder
 19. 909.0 Late effect of poisoning due to drug, medicinal or biological substance
 20. 977.9 Poisoning by other and unspecified drugs and medicinal substances
 21. E858.9 Accidental poisoning by other drugs, unspecified drug
 22. E950.5* Self-inflicted injury, unspecified drug or medicinal substance
 23. E980.5* Injury undetermined whether accidentally or purposely inflicted, unspecified drug or medicinal substance
 24. E950.9* Self-inflicted injury, other and unspecified solid and liquid substances
 25. E980.9* Injury undetermined whether accidentally or purposely inflicted, other and unspecified solid and liquid substances
Table 7 ICD9-CM diagnosis codes indicating potential adverse effects for medications used in a therapeutically appropri-
ate manner
We exclude dermatitis (692.3, topical) as no topical drugs are included in the study.
Code Diagnosis
A. Opioid or unspecified analgesic
 1. E935.0 Analgesics, antipyretics, and antirheumatics, heroin
 2. E935.1 Analgesics, antipyretics, and antirheumatics, methadone
 3. E935.2 Analgesics, antipyretics, and antirheumatics, other opiates and related narcotics
 4. E935.8 Analgesics, antipyretics, and antirheumatics, pentazocine
 5. E935.9 Analgesics, antipyretics, and antirheumatics, unspecified analgesic or antipyretic
B. Other specified medication. For ranges, code only qualifies if not otherwise listed (in A, C)
 6. E930–E947.9
C. Unspecified medication
 7. 693.0 Dermatitis due to substances taken internally, drugs and medications
 8. 909.5 Late effect of adverse effect of drug, medicinal or biological substance
 9. 995.2 Other and unspecified adverse effect of drug, medicinal and biological substance 
(due) to correct medicinal substance properly administered
 10. E947.9 Unspecified drug or medicinal substance
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Table 8 ICD9-CM diagnosis codes for opioid respiratory or 
CNS symptoms
a Does not include pneumonia (486), chronic airway obstruction (496), 
shortness of breath (786.05,786.09), or painful respiration (786.52). Based on 
the preliminary analysis, also does not include symptoms: 786.00 respiratory 
abnormality, unspecified, 786.03 apnea, 799.0 asphyxia and hypoxemia, 799.01 
asphyxia, 799.02 hypoxemia, 799.1 respiratory arrest. Pilot indicated very low 
PPV for these latter codes.
b For the day the prescription was filled or the preceding 6 days, no encounter 
with a diagnosis of pneumonia or other respiratory infections, pleural effusion, 
pneumothorax; or a procedure for thoracentesis or thoracostomy.
c Does not include dizziness (780.4) or abnormal gait (781.2).
Code Diagnosis
A. Respiratory depressiona in the absence of known causesb
 1. 518.0 Pulmonary collapse
 2. 518.81 Acute respiratory failure
 3. 518.82 Other pulmonary insufficiency, not elsewhere classified
 4. 518.84 Acute and chronic respiratory failure
B. Central nervous systemc
 5. 780.0 Alteration of consciousness
 6. 780.01 Coma
 7. 780.02 Transient alteration of awareness
 8. 780.09 Other alteration of consciousness
 9. 780.1 Hallucinations
 10. 780.97 Altered mental state
 11. 781.3 Lack of coordination
